全文获取类型
收费全文 | 976篇 |
免费 | 57篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 20篇 |
妇产科学 | 12篇 |
基础医学 | 136篇 |
口腔科学 | 6篇 |
临床医学 | 102篇 |
内科学 | 270篇 |
皮肤病学 | 19篇 |
神经病学 | 116篇 |
特种医学 | 26篇 |
外科学 | 142篇 |
综合类 | 6篇 |
预防医学 | 26篇 |
眼科学 | 22篇 |
药学 | 83篇 |
中国医学 | 3篇 |
肿瘤学 | 43篇 |
出版年
2021年 | 4篇 |
2020年 | 9篇 |
2019年 | 10篇 |
2018年 | 13篇 |
2017年 | 4篇 |
2016年 | 18篇 |
2015年 | 20篇 |
2014年 | 28篇 |
2013年 | 44篇 |
2012年 | 58篇 |
2011年 | 64篇 |
2010年 | 47篇 |
2009年 | 48篇 |
2008年 | 52篇 |
2007年 | 76篇 |
2006年 | 50篇 |
2005年 | 70篇 |
2004年 | 52篇 |
2003年 | 44篇 |
2002年 | 58篇 |
2001年 | 4篇 |
1999年 | 9篇 |
1998年 | 12篇 |
1997年 | 9篇 |
1996年 | 9篇 |
1995年 | 12篇 |
1994年 | 6篇 |
1993年 | 14篇 |
1992年 | 6篇 |
1987年 | 4篇 |
1986年 | 6篇 |
1985年 | 4篇 |
1984年 | 7篇 |
1983年 | 9篇 |
1981年 | 4篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1976年 | 4篇 |
1974年 | 5篇 |
1973年 | 4篇 |
1963年 | 5篇 |
1948年 | 3篇 |
1938年 | 3篇 |
1928年 | 3篇 |
1926年 | 4篇 |
1925年 | 3篇 |
1924年 | 5篇 |
1914年 | 3篇 |
1895年 | 3篇 |
1890年 | 3篇 |
排序方式: 共有1036条查询结果,搜索用时 15 毫秒
31.
Lisa Pleyer Sonja Burgstaller Michael Girschikofsky Werner Linkesch Reinhard Stauder Michael Pfeilstocker Martin Schreder Christoph Tinchon Thamer Sliwa Alois Lang Wolfgang R. Sperr Peter Krippl Dietmar Geissler Daniela Voskova Konstantin Schlick Josef Thaler Sigrid Machherndl-Spandl Georg Theiler Otto Eckmüllner Richard Greil 《Annals of hematology》2014,93(11):1825-1838
Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian Azacitidine Registry (clinicaltrials.gov identifier NCT01595295). We herein update this report with a population almost twice as large (n?=?302). This cohort included 172 patients with >30 % BM blasts; 93 % would have been excluded from the pivotal AZA-001 trial (which led to European Medicines Agency (EMA) approval of azacitidine for high-risk myelodysplastic syndromes (MDS) and AML with 20–30 % BM blasts). Despite this much more unfavorable profile, results are encouraging: overall response rate was 48 % in the total cohort and 72 % in patients evaluable according to MDS-IWG-2006 response criteria, respectively. Median OS was 9.6 (95 % CI 8.53–10.7)?months. A clinically relevant OS benefit was observed with any form of disease stabilization (marrow stable disease (8.1 months), hematologic improvement (HI) (9.7 months), or the combination thereof (18.9 months)), as compared to patients without response and/or without disease stabilization (3.2 months). Age, white blood cell count, and BM blast count at start of therapy did not influence OS. The baseline factors LDH >225 U/l, ECOG ≥2, comorbidities ≥3, monosomal karyotype, and prior disease-modifying drugs, as well as the response-related factors hematologic improvement and further deepening of response after first response, were significant independent predictors of OS in multivariate analysis. Azacitidine seems effective in WHO-AML, including patients with >30 % BM blasts (currently off-label use). Although currently not regarded as standard form of response assessment in AML, disease stabilization and/or HI should be considered sufficient response to continue treatment with azacitidine. 相似文献
32.
Keser Tobias Kofler Mario Katzmayr Mariella Schiefecker Alois J. Rass Verena Ianosi Bogdan A. Lindner Anna Gaasch Maxime Beer Ronny Rhomberg Paul Schmutzhard Erich Pfausler Bettina Helbok Raimund 《Neurocritical care》2020,33(1):132-139
Neurocritical Care - Despite the tremendous impact of swallowing disorders on outcome following ischemic stroke, little is known about the incidence of dysphagia after subarachnoid hemorrhage (SAH)... 相似文献
33.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study 总被引:50,自引:45,他引:50
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Talpaz M Silver RT Druker BJ Goldman JM Gambacorti-Passerini C Guilhot F Schiffer CA Fischer T Deininger MW Lennard AL Hochhaus A Ottmann OG Gratwohl A Baccarani M Stone R Tura S Mahon FX Fernandes-Reese S Gathmann I Capdeville R Kantarjian HM Sawyers CL 《Blood》2002,99(6):1928-1937
Chronic myelogenous leukemia (CML) is caused by expression of the BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Patients with CML in accelerated phase have rapidly progressive disease and are characteristically unresponsive to existing therapies. Imatinib (formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl kinase. A total of 235 CML patients were enrolled in this study, of whom 181 had a confirmed diagnosis of accelerated phase. Patients were treated with imatinib at 400 or 600 mg/d and were evaluated for hematologic and cytogenetic response, time to progression, survival, and toxicity. Imatinib induced hematologic response in 82% of patients and sustained hematologic responses lasting at least 4 weeks in 69% (complete in 34%). The rate of major cytogenetic response was 24% (complete in 17%). Estimated 12-month progression-free and overall survival rates were 59% and 74%, respectively. Nonhematologic toxicity was usually mild or moderate, and hematologic toxicity was manageable. In comparison to 400 mg, imatinib doses of 600 mg/d led to more cytogenetic responses (28% compared to 16%), longer duration of response (79% compared to 57% at 12 months), time to disease progression (67% compared to 44% at 12 months), and overall survival (78% compared to 65% at 12 months), with no clinically relevant increase in toxicity. Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity. 相似文献
34.
Vanda Toth Andras Fogarasi Kazmer Karadi Norbert Kovacs Alois Ebner Jozsef Janszky 《Epilepsia》2010,51(7):1126-1132
Purpose: We systematically analyzed the video‐recorded and patient‐reported, as well as positive and negative ictal affective symptoms (IAS) in temporal lobe epilepsy (TLE). Our aim was to assess (1) frequency, (2) gender effect, (3) lateralizing significance, (4) localizing value, and (5) prognostic significance in epilepsy surgery of IAS in patients with video‐registered seizures. Methods: We reviewed ictal video recordings of 184 patients (99 women, aged 16–63). All patients had surgery for intractable TLE with video‐recorded complex partial seizures (CPS) due to temporal lobe lesions visualized by high‐resolution magnetic resonance imaging (MRI). Affective auras (AAs) were categorized into two groups: positive or negative. Results: We registered AAs in 18% of patients: positive in 3%, negative in 15%. We saw ictal affective behavior (IAB) in 22% of patients; 10% had positive, whereas 14% had negative IAB. Two patients had both positive and negative IAB. AAs showed an association with IAB in case of fear expression versus fear auras (p = 0.018). IAB, especially negative IAB, occurred more often in women than in men. Patients with negative IAB were younger than others. We could not demonstrate an association between IAS and the localization, lateralization, or hemispheric dominance. Surgical outcome did not associate with IAS. Discussion: Patient‐reported and video‐recorded negative—but not positive—affective signs are related to each other. Video‐recorded negative AAs occur more often in women and young patients. 相似文献
35.
36.
Dalla Vestra M Sacerdoti D Bombonato G Fioretto P Finucci G Saller A Sfriso A Bruseghin M Sambataro M Velussi M Baggio B Nosadini R Crepaldi G 《European journal of endocrinology / European Federation of Endocrine Societies》2002,146(5):687-694
OBJECTIVE: To evaluate endothelial function in type 2 diabetic patients with and without diabetic nephropathy. METHODS: We studied the effects of systemic infusion of the nitric oxide (NO) synthase inhibitor NG-monomethyl-l-arginine (L-NMMA) on cardiovascular and renal hemodynamics in six type 2 diabetic patients with microalbuminuria (D2-MA), six type 2 diabetic patients with normoalbuminuria (D2-NA) and five control subjects. Both type 2 diabetic patients and control subjects had mild arterial hypertension. RESULTS: L-NMMA infusion decreased the cardiac index in all groups. A reduction in glomerular filtration rate (GFR) and an increase in filtration fraction were observed only in controls. Renal plasma flow decreased in controls and D2-NA patients and renal vascular resistance increased in all groups. CONCLUSIONS: The effect of L-NMMA on cardiac output was similar in controls and type 2 diabetic patients with and without diabetic nephropathy. In contrast, the effect on GFR was impaired in both diabetic groups, suggesting that glomerular NO homeostasis is altered in type 2 diabetes. Moreover the discrepancy, in diabetic patients, between cardiac and renal effects during L-NMMA infusion suggests that the modulation of glomerular hemodynamics is independent from NO-regulated cardiac output. 相似文献
37.
38.
The EuroConference/Neurochemistry Winter Conference on Modeling Addiction, held on 6-11 April 2002 in Soelden, Austria(1) explored the question of how various experimental approaches, ranging from those at the level of molecular biology to human behavior, reflect human patterns of drug abuse and dependence and whether these various approaches constitute suitable predictive or homologous models to test novel pharmacotherapies. 相似文献
39.
Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients 总被引:18,自引:0,他引:18
Mussap M Dalla Vestra M Fioretto P Saller A Varagnolo M Nosadini R Plebani M 《Kidney international》2002,61(4):1453-1461
BACKGROUND: Glomerular filtration rate (GFR) is the best overall index of renal function in health and disease. Inulin and 51Cr-EDTA plasma clearances are considered the gold standard methods for estimating GFR. Unfortunately, these methods require specialized technical personnel over a period of several hours and high costs. In clinical practice, serum creatinine is the most widely used index for the noninvasive assessment of GFR. Despite its specificity, serum creatinine demonstrates an inadequate sensitivity, particularly in the early stages of renal impairment. Recently, cystatin C, a low molecular mass plasma protein freely filtered through the glomerulus and almost completely reabsorbed and catabolized by tubular cells, has been proposed as a new and very sensitive serum marker of changes in GFR. This study was designed to test whether serum cystatin C can replace serum creatinine for the early assessment of nephropathy in patients with type 2 diabetes. METHODS: The study was performed on 52 Caucasian type 2 diabetic patients. Patients with an abnormal albumin excretion rate (AER) were carefully examined to rule out non-diabetic renal diseases by ultrasonography, urine bacteriology, microscopic urine analysis, and kidney biopsy. Serum creatinine, serum cystatin C, AER, serum lipids, and glycosylated hemoglobin (HbA1c) were measured. GFR was estimated by the plasma clearance of 51Cr-EDTA. In addition the Cockcroft and Gault formula (Cockcroft and Gault estimated GFR) was calculated. RESULTS: Cystatin C serum concentration progressively increased as GFR decreased. The overall relationship between the reciprocal cystatin C and GFR was significantly stronger (r = 0.84) than those between serum creatinine and GFR (r = 0.65) and between Cockcroft and Gault estimated GFR and GFR (r = 0.70). As GFR decreased from 120 to 20 mL/min/1.73 m2, cystatin C increased more significantly that serum creatinine, giving a stronger signal in comparison to that of creatinine over the range of the measured GFR. The maximum diagnostic accuracy of serum cystatin C (90%) was significantly better than those of serum creatinine (77%) and Cockcroft and Gault estimated GFR (85%) in discriminating between type 2 diabetic patients with normal GFR (>80 mL/min per 1.73 m2) and those with reduced GFR (<80 mL/min/1.73 m2). In particular, the cystatin C cut-off limit of 0.93 mg/L corresponded to a false-positive rate of 7.7% and to a false-negative rate of 1.9%; the serum creatinine cut-off limit of 87.5 micromol/L corresponded to a false-positive rate of 5.8% and to a false-negative rate of 17.0%. CONCLUSIONS: Cystatin C may be considered as an alternative and more accurate serum marker than serum creatinine or the Cockcroft and Gault estimated GFR in discriminating type 2 diabetic patients with reduced GFR from those with normal GFR. 相似文献
40.
Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells 总被引:4,自引:0,他引:4
BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is known for its selective cytotoxic activity on tumour cells. We analysed the response of HT-29 human colon carcinoma cells to this cytokine. MATERIALS AND METHODS: After TNF-alpha treatment, cell proliferation, cell cycle, reactive oxygen species (ROS) production (flow cytometry), the amount of apoptotic cells (flow cytometry, fluorescence microscopy), cleavage of poly (ADP-ribose) polymerase (PARP) and caspase-3 activity (Western blotting) were detected. RESULTS: TNF-alpha induced a decrease of cell growth and viability, an accumulation of cells in the S-phase of the cell cycle, an increase of subdiploid cell population and nuclear chromatin condensation and fragmentation, but not sooner than 96-120 hours. However, earlier events characteristic of apoptosis occurred, such as caspase-3 activation, PARP cleavage to 89 kDa fragment and changes in ROS production. CONCLUSION: We demonstrated that, in addition to being an early marker of apoptosis, activation of caspase-3 and degradation of PARP may play a causative role in HT-29 cell death induced by TNF-alpha. 相似文献